Telomir Pharmaceuticals’ stock soared on 18 July after the preclinical-stage biotech reported that its candidate Telomir-1 fully reversed epigenetic silencing of the STAT1 tumor-suppressor gene in an aggressive human prostate cancer model, outperforming standard therapies Paclitaxel and Rapamycin. In a 21-day oral PC3 xenograft study, the compound also reduced hypermethylation of the TMS1 gene without elongating cancer-cell telomeres, pointing to a favourable safety profile. The results build on March data showing roughly 50 per cent tumour shrinkage and the elimination of chemotherapy-induced mortality when Telomir-1 was combined with Paclitaxel. Investors reacted swiftly: Telomir shares climbed as much as 150 per cent in pre-market trading and finished the session up about 88 per cent, ranking among the day’s top performers on Nasdaq. The Miami-based company remains at the preclinical stage and has yet to file an Investigational New Drug application. Management said additional toxicology work is under way and that it will announce an initial clinical indication and development timeline once those studies are complete.